Poseida Therapeutics, Inc. Research and Development Expense
Poseida Therapeutics, Inc. reported Research and Development Expense of $41.91 million for the 3-month period ending 2024-09-30, per its 10-Q filed 2024-11-07.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2024-11-07
- Poseida Therapeutics, Inc. research and development expense for the quarter ending 2024-09-30 was $41.91M, a 11.82% increase year-over-year.
- Poseida Therapeutics, Inc. research and development expense for the quarter ending 2024-06-30 was $45.55M, a 16.22% increase year-over-year.
- Poseida Therapeutics, Inc. research and development expense for the quarter ending 2024-03-31 was $42.92M, a 12.80% increase year-over-year.
- Poseida Therapeutics, Inc. research and development expense for the quarter ending 2023-12-31 was $42.05M, a 24.01% increase year-over-year.
- Poseida Therapeutics, Inc. research and development expense for fiscal 2023 was $156.77M, a 2.53% increase from fiscal 2022.
- Poseida Therapeutics, Inc. research and development expense for fiscal 2022 was $152.90M, a 11.82% increase from fiscal 2021.
- Poseida Therapeutics, Inc. research and development expense for fiscal 2021 was $136.73M, a 32.08% increase from fiscal 2020.
- Poseida Therapeutics, Inc. research and development expense for fiscal 2020 was $103.52M, a 71.41% increase from fiscal 2019.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2024-09-30 | $41.91M 10-Q · filed 2024-11-07 | $87.46M derived: sum of 2 quarters · filed 2024-11-07 | $130.38M 10-Q · filed 2024-11-07 | $172.43M derived: sum of 4 quarters · filed 2024-11-07 |
| 2024-06-30 | $45.55M 10-Q · filed 2024-08-05 | $88.47M 10-Q · filed 2024-08-05 | $130.51M derived: sum of 3 quarters · filed 2024-08-05 | $168.00M derived: sum of 4 quarters · filed 2024-11-07 |
| 2024-03-31 | $42.92M 10-Q · filed 2024-05-14 | $84.97M derived: sum of 2 quarters · filed 2024-05-14 | $122.45M derived: sum of 3 quarters · filed 2024-11-07 | $161.64M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-12-31 | $42.05M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-07 | $79.53M derived: sum of 2 quarters · filed 2024-11-07 | $118.72M derived: sum of 3 quarters · filed 2024-11-07 | $156.77M 10-K · filed 2024-03-07 |
| 2023-09-30 | $37.48M 10-Q · filed 2024-11-07 | $76.67M derived: sum of 2 quarters · filed 2024-11-07 | $114.73M 10-Q · filed 2024-11-07 | $148.63M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $39.19M 10-Q · filed 2024-08-05 | $77.24M 10-Q · filed 2024-08-05 | $111.15M derived: sum of 3 quarters · filed 2024-08-05 | $146.28M derived: sum of 4 quarters · filed 2024-08-05 |
| 2023-03-31 | $38.05M 10-Q · filed 2024-05-14 | $71.96M derived: sum of 2 quarters · filed 2024-05-14 | $107.09M derived: sum of 3 quarters · filed 2024-05-14 | $142.10M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | $33.90M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-07 | $69.04M derived: sum of 2 quarters · filed 2024-03-07 | $104.05M derived: sum of 3 quarters · filed 2024-03-07 | $152.90M 10-K · filed 2024-03-07 |
| 2022-09-30 | $35.14M 10-Q · filed 2023-11-09 | $70.14M derived: sum of 2 quarters · filed 2023-11-09 | $119.00M 10-Q · filed 2023-11-09 | $158.10M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $35.01M 10-Q · filed 2023-08-08 | $83.86M 10-Q · filed 2023-08-08 | $122.97M derived: sum of 3 quarters · filed 2023-08-08 | $155.49M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | $48.85M 10-Q · filed 2023-05-09 | $87.96M derived: sum of 2 quarters · filed 2023-05-09 | $120.48M derived: sum of 3 quarters · filed 2023-05-09 | $156.49M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $39.11M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $71.63M derived: sum of 2 quarters · filed 2023-03-09 | $107.64M derived: sum of 3 quarters · filed 2023-03-09 | $136.73M 10-K · filed 2023-03-09 |
| 2021-09-30 | $32.52M 10-Q · filed 2022-11-10 | $68.53M derived: sum of 2 quarters · filed 2022-11-10 | $97.63M 10-Q · filed 2022-11-10 | $125.51M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $36.01M 10-Q · filed 2022-08-11 | $65.10M 10-Q · filed 2022-08-11 | $92.99M derived: sum of 3 quarters · filed 2022-08-11 | $120.00M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $29.09M 10-Q · filed 2022-05-12 | $56.98M derived: sum of 2 quarters · filed 2022-05-12 | $84.00M derived: sum of 3 quarters · filed 2022-05-12 | $109.20M derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | $27.88M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | $54.90M derived: sum of 2 quarters · filed 2022-03-10 | $80.11M derived: sum of 3 quarters · filed 2022-03-10 | $103.52M 10-K · filed 2022-03-10 |
| 2020-09-30 | $27.02M 10-Q · filed 2021-11-09 | $52.23M derived: sum of 2 quarters · filed 2021-11-09 | $75.64M 10-Q · filed 2021-11-09 | $94.84M derived: sum of 4 quarters · filed 2021-11-09 |
| 2020-06-30 | $25.21M 10-Q · filed 2021-08-12 | $48.63M 10-Q · filed 2021-08-12 | $67.83M derived: sum of 3 quarters · filed 2021-08-12 | $83.52M derived: sum of 4 quarters · filed 2021-08-12 |
| 2020-03-31 | $23.41M 10-Q · filed 2021-05-11 | $42.62M derived: sum of 2 quarters · filed 2021-05-11 | $58.31M derived: sum of 3 quarters · filed 2021-05-11 | $75.19M derived: sum of 4 quarters · filed 2021-05-11 |
| 2019-12-31 | $19.20M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-11 | $34.90M derived: sum of 2 quarters · filed 2021-03-11 | $51.78M derived: sum of 3 quarters · filed 2021-03-11 | $60.39M 10-K · filed 2021-03-11 |
| 2019-09-30 | $15.70M 10-Q · filed 2020-11-12 | $32.58M derived: sum of 2 quarters · filed 2020-11-12 | $41.19M 10-Q · filed 2020-11-12 | |
| 2019-06-30 | $16.88M 10-Q · filed 2020-08-20 | $25.49M 10-Q · filed 2020-08-20 |